Why we close the appendage
In atrial fibrillation, the upper chambers don’t contract effectively, and blood tends to pool. The single most clot-prone spot in the entire left atrium is a small, finger-shaped pouch on its outer wall called the left atrial appendage. In non-valvular AFib, more than 9 out of 10 stroke-causing clots originate from this one pouch. Long-term blood thinners work by preventing clot formation throughout the bloodstream, including the appendage — but the daily bleeding risk that comes with anticoagulation applies everywhere, every day.
The idea behind WATCHMAN is straightforward: if almost all of the stroke risk comes from this one pouch, sealing it off should let most patients safely stop the blood thinner. Multiple large clinical trials have shown that stroke prevention with WATCHMAN is comparable to long-term anticoagulation, while sparing patients the long-term bleeding risks of daily blood thinners.
The currently FDA-approved WATCHMAN device in the United States is the Boston Scientific WATCHMAN FLX.
What the device looks like and how it works
The WATCHMAN (and its current generation, WATCHMAN FLX) is a small, parachute-shaped device made of a flexible metal frame covered by a thin fabric membrane. It comes in several sizes, picked based on imaging of the appendage. Once deployed, the device opens up inside the appendage opening, anchors gently against its walls with small fixation hooks, and the fabric face blocks blood from entering the pouch. Over the following weeks, the body’s own tissue grows across the fabric surface, sealing the appendage off permanently from the rest of the atrium.
How the procedure goes
The implant is done in a procedure room under general anesthesia. A transesophageal echo probe (a slim ultrasound probe down the esophagus) gives us a continuous, detailed view of the appendage and the device throughout. We access a vein in the groin, cross from the right atrium to the left through a small puncture in the wall between them, and steer the delivery system into the mouth of the appendage. The device is unsheathed, allowed to open inside the appendage, sized against the wall, and tested for stability and seal. Once we’re confident it’s well-positioned, we release it.
The procedure itself is usually under an hour and a half, and most patients go home the same day or the next morning.
The 45-day plan
For the first 45 days, you stay on your blood thinner along with low-dose aspirin. This period is critical because the body needs time to heal a layer of tissue across the device’s surface; until that happens, the device itself can attract small clots.
At about 45 days, we bring you back for a transesophageal echo to look at three things: Is the appendage fully sealed? Is the device stable in position? Is there any clot on its atrial side? If all three answers are reassuring — which is the case for most patients — we stop the blood thinner. Low-dose aspirin is typically continued for several months afterward; long-term, many patients continue only aspirin, and even that is reconsidered over time.
If there is a small leak or a clot on the device, we extend anticoagulation and recheck. In most cases, time and a few more weeks of blood thinning resolve it.
Who is a candidate
WATCHMAN is for patients with non-valvular atrial fibrillation who have:
- A meaningful stroke risk based on the CHA₂DS₂-VASc score.
- A specific reason that long-term anticoagulation is problematic — for example, history of a major bleed, recurrent GI bleeding, frequent falls with traumatic bleeding, intracranial hemorrhage, occupations or lifestyles that make bleeding particularly hazardous, or simply an inability to tolerate available anticoagulants.
It is not an alternative for patients who can take and would benefit from an anticoagulant without difficulty — for most AFib patients, the blood thinner is still the standard. WATCHMAN is also not for patients with mechanical heart valves, rheumatic mitral stenosis, or clots already present in the appendage at the time of evaluation.
What WATCHMAN does and doesn’t address
Closing the appendage addresses stroke risk from the appendage clot pathway — the dominant pathway in non-valvular AFib. It does not treat the AFib itself: the rhythm will still come and go, the heart rate may still need to be controlled with medications, and ablation remains a separate question. Likewise, WATCHMAN does not prevent clots that form elsewhere in the bloodstream — patients who have other indications for anticoagulation (deep vein thrombosis, mechanical valve, certain other thromboembolic conditions) still need their blood thinner for that reason.
We work through the full picture with you — your stroke risk, your bleeding history, your other medical issues, and your preferences — to figure out whether WATCHMAN is the right step.
Manufacturer reference
For technical specifications, indications, and the latest official information on the WATCHMAN FLX system from its maker, see Boston Scientific’s product pages:
(External links — content is Boston Scientific’s and may be technical.)